Cargando…
Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?
This review summarizes the various conceptual paradigms for treating schizophrenia, and indicates how molecular biology and drug discovery technologies can accelerate the development of new medications. As yet, there is no convincing data that a crucial druggable molecular target exists which, if ta...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Les Laboratoires Servier
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181824/ https://www.ncbi.nlm.nih.gov/pubmed/17117612 |
_version_ | 1782212820611366912 |
---|---|
author | Roth, Bryan L. |
author_facet | Roth, Bryan L. |
author_sort | Roth, Bryan L. |
collection | PubMed |
description | This review summarizes the various conceptual paradigms for treating schizophrenia, and indicates how molecular biology and drug discovery technologies can accelerate the development of new medications. As yet, there is no convincing data that a crucial druggable molecular target exists which, if targeted, would yield medications with efficacies greater than any currently available. It is suggested, instead, that drugs which interact with a multiplicity of molecular targets are likely to show greater efficacy in treating the core symptoms of schizophrenia. |
format | Online Article Text |
id | pubmed-3181824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Les Laboratoires Servier |
record_format | MEDLINE/PubMed |
spelling | pubmed-31818242011-10-27 Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? Roth, Bryan L. Dialogues Clin Neurosci Pharmacological Aspects This review summarizes the various conceptual paradigms for treating schizophrenia, and indicates how molecular biology and drug discovery technologies can accelerate the development of new medications. As yet, there is no convincing data that a crucial druggable molecular target exists which, if targeted, would yield medications with efficacies greater than any currently available. It is suggested, instead, that drugs which interact with a multiplicity of molecular targets are likely to show greater efficacy in treating the core symptoms of schizophrenia. Les Laboratoires Servier 2006-09 /pmc/articles/PMC3181824/ /pubmed/17117612 Text en Copyright: © 2006 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pharmacological Aspects Roth, Bryan L. Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? |
title | Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? |
title_full | Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? |
title_fullStr | Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? |
title_full_unstemmed | Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? |
title_short | Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? |
title_sort | contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled? |
topic | Pharmacological Aspects |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181824/ https://www.ncbi.nlm.nih.gov/pubmed/17117612 |
work_keys_str_mv | AT rothbryanl contributionsofmolecularbiologytoantipsychoticdrugdiscoverypromisesfulfilledorunfulfilled |